Erratum: High-density lipoprotein is superior to B-type natriuretic peptide as a marker of systolic dysfunction in an elderly general population (Scandinavian Journal of Clinical and Laboratory Investigation (2009) 69 (865-872) DOI: 10.3109/00365510903359237);High-density lipoprotein is superior to B-type natriuretic peptide as a marker of systolic dysfunction in an elderly general population

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 8, 2009, Pages 865-872

  Kerola, Tuomas ^a   Nieminen, Tuomo ^a,b   Hartikainen, Sirpa ^c   Sulkava, Raimo ^c   Vuolteenaho, Olli ^d   Kettunen, Raimo ^a  

^a PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d UNIVERSITY OF OULU   (Finland)

Author keywords

Cohort study; Ejection fraction; Heart failure; Lipids; Natriuretic peptides; Population based study

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; ECHOCARDIOGRAPHY; FEMALE; FINLAND; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HUMAN; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION;

EID: 72749108670     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365511003775780     Document Type: Erratum

References (34)

1. Bursi F, Weston SA, Redfi eld MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger, VL. Systolic and diastolic heart failure in the community. J Am Med Ass 2006;296:2209-2216
2. Levy D, Kenchaiah S, Larson MG. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1398-1402
3. Rudiger A, Harjola VP, Mueller A. Acute heart failure: Clinical presentation, one-year mortality and prognostic factors. Eur J Heart Fail 2005;7:662-670
4. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327: 669-677
5. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992;327:685-691
6. Redfi eld MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. J Am Med Ass 2003;289:194-202.
7. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003;362:777-781
8. Kupari M, Lindroos M, Iivanainen AM, Heikkila J, Tilvis R. Congestive heart failure in old age: Prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med 1997;241:387-394
9. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH, Apple FS, Ravkilde J, Wu AH. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007;116:e99-109.
10. Hutcheon SD, Gillespie ND, Struthers AD, McMurdo ME. B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. Age Ageing 2002;31:295-301.
11. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004;90:297-303.
12. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham heart study. J Am Med Ass 2002;288:1252-1259
13. McDonagh TA, Cunningham AD, Morrison CE, McMurray JJ, Ford I, Morton JJ, Dargie HJ. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001;86:21-26
14. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004;43:1019-1026
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
16. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of infl ammation in nonischemic heart failure. J Am Coll Cardiol 2006;47:332-337
17. Talini E, Di Bello V, Bianchi C, Palagi C, Delle Donne MG, Penno G, Nardi C, Canale ML, Del Prato S, Mariani M, Miccoli R. Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin A preliminary echocardiographic study. Atherosclerosis 2008;197:346-354
18. Wang TD, Lee CM, Wu CC, Lee TM, Chen WJ, Chen MF, Liau CS, Sung FC, Lee YT. The effects of dyslipidemia on left ventricular systolic function in patients with stable angina pectoris. Atherosclerosis 1999;146: 117-124
19. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083
20. Folland ED, Parisi AF, Moynihan PF, Jones DR, Feldman CL, Tow DE. Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. Acomparison of cineangiographic and radionuclide techniques. Circulation 1979;60: 760-766
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
23. Vuolteenaho O, Koistinen P, Martikkala V, Takala T, Leppaluoto J. Effect of physical exercise in hypobaric conditions on atrial natriuretic peptide secretion. Am J Physiol 1992;263:647-652
24. Vuolteenaho O, Arjamaa O, Ling N. Atrial natriuretic polypeptides (ANP): Rat atria store high molecular weight precursor but secrete processed peptides of 25-35 amino acids. Biochem Biophys Res Commun 1985;129:82-88
25. Banka CL. High density lipoprotein and lipoprotein oxidation. Curr Opin Lipidol 1996;7:139-142
26. Sviridov D, Mukhamedova N, Remaley A, Chin-Dusting J, Nestel P. Antiatherogenic functionality of high density lipoprotein: How much versus how good. J Atheroscler Thromb 2008;15:52-62.
27. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: Pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 2009;11:444-452
28. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhai XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW. Shotgun proteomics implicates protease inhibition and complement activation in the anti-infl ammatory properties of HDL. J Clin Invest 2007;117:746-756
29. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350: 1119-1123
30. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. J Am Med Ass 2006;296:2105-2111
31. Smith H, Pickering RM, Struthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: Observational study. Br Med J 2000;320:906-908
32. Alehagen U, Lindstedt G, Eriksson H, Dahlstrom U. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem 2003;49:1337-1346
33. Pyörälä K, Salonen JT, Valkonen T. Trends in coronary heart disease mortality and morbidity and related factors in Finland. Cardiology 1985;72:35-51. (Pubitemid 15163598)
34. Ishii J, Nomura M, Ito M, Naruse H, Mori Y, Wang J-h, Ishikawa T, Kurokawa H, Kondo T, Nagamura Y, Ezaki K, Watanabe Y, Hishida H. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta 2000;301:19-30.